Thoracic Aneurysm

Back

Background

Thoracic aortic aneurysm (TAA) is a life-threatening condition that causes significant short- and long-term mortality due to rupture and dissection. Aneurysm is defined as dilatation of the aorta of greater than 150% of its normal diameter for a given segment. For the thoracic aorta, a diameter greater than 3.5 cm is generally considered dilated, whereas greater than 4.5 cm would be considered aneurysmal.

Aneurysms may affect one or more segments of the thoracic aorta, including the ascending aorta, the arch, and the descending thoracic aorta. As many as 25% of patients with TAA also have an abdominal aortic aneurysm. Thoracic aortic aneurysm most commonly results from degeneration of the media of the aortic wall as well as from local hemodynamic forces.



View Image

Descending thoracic aortic aneurysm with mural thrombus at the level of the left atrium.

Pathophysiology

Degenerative changes in the wall of the aorta lead to cystic medial necrosis. This causes damage to collagen and elastin, loss of smooth muscle cells, and increased amounts of basophilic ground substance in the medial (elastic) layer of the aorta. The ascending thoracic aorta is generally most affected by cystic medial necrosis, whereas a descending thoracic aneurysm is primarily a consequence of atherosclerosis.

In Marfan syndrome, abnormalities of the gene encoding for the synthesis of fibrillin have been implicated in the predisposition to form aneurysms. Mutations in the gene responsible for this structural lipoprotein found in the aortic wall have been found in patients who do not have Marfan syndrome but have aneurysms.

As many as 75% of patients with a bicuspid aortic valve have shown evidence for cystic medial necrosis, which may be because of inadequate fibrillin production. Other inherited forms of medial degeneration have been associated with defects in the genes for fibrillin and are associated with higher rates of thoracic aortic aneurysm (TAA).

Weakening of the aortic wall is compounded by increased shear stress, especially in the ascending aorta. This segment of the aorta is most exposed to the pressure of each cardiac systole (dP/dt) as well as the dynamic heart motion transmitted from each cardiac cycle. As local wall weakness causes dilatation of the aorta, wall tension increases (described by the Laplace law (T=PR), where wall tension equals the radius of a cylinder multiplied by the pressure within it). Small tears in the intimal (innermost) layer of the aorta can permit blood to penetrate the medial layer, leading to aortic dissection.

Epidemiology

Frequency

United States

The incidence of aortic aneurysm is 5.9 cases per 100,000 person-years.[1]

Mortality/Morbidity

The cumulative risk of rupturing a thoracic aortic aneurysm (TAA) is related to aneurysm diameter. In a recent series of 133 patients with TAA, risk of rupture at 5 years was 0% for diameter less than 4 cm, 16% for diameter 4-5.9 cm, and 31% for aneurysms greater than 6 cm in diameter.[2]

Race

Thoracic aortic aneurysm is most common among whites.

Sex

Men are affected 2-4 times more frequently than women.

Age

The mean patient age at diagnosis is 60-65 years.

History

Patients with thoracic aortic aneurysm (TAA) may be asymptomatic. Forty percent may be found incidentally during workup for other processes. Symptoms vary according to the size, location, and changes in the aneurysm. Chest, back, and abdominal pain are common symptoms in patients who are symptomatic. Note the following:

Physical

The physical examination findings are usually normal. Note the following:

Causes

Although atherosclerotic disease is often present in patients with thoracic aortic aneurysm (TAA), it may only play a minor causal role in the pathogenesis of aneurysm development. Note the following:

Laboratory Studies

Hematocrit may be lowered in patients with a ruptured aneurysm.

Coagulation studies may demonstrate coagulopathy.

BUN and creatinine levels may be elevated in patients with shock and renal hypoperfusion.

A blood bank sample should be ordered.

Creatine kinase (CK) and troponin levels may be measured to assess for myocardial infarction.

Imaging Studies

CT scanning, MRI, angiography, and transesophageal echocardiography are most often used to assess thoracic aneurysm in the emergent setting. The preferred method of assessment depends on the stability of the patient, the availability of radiographic modalities, and the preference of the surgeon. However, CT scanning is most commonly used in both emergent and outpatient settings to diagnose and follow thoracic aneurysm.

Chest radiography

Thoracic CT scanning

Contrast angiography

Magnetic resonance angiography

Transesophageal echocardiography

Other Tests

Electrocardiography

Prehospital Care

In patients with symptoms suggestive of thoracic aortic aneurysm (TAA), prehospital care should consist of ensuring adequate airway and breathing, providing oxygen via a nonrebreather mask, placing 2 large-bore intravenous lines, and providing continuous cardiac monitoring.

Patients who are unstable (often those with a ruptured aneurysm or dissection) may require airway protection, mechanical ventilation, and aggressive fluid resuscitation. Timely communication between prehospital care providers and the receiving hospital is important in ensuring that the proper resources are available and brought to bear rapidly.

Emergency Department Care

Initial stabilization includes the following:

Consider alternate diagnoses. Until the diagnosis of thoracic aortic aneurysm (TAA) is established, be vigilant for other causes of symptoms, such as myocardial infarction (MI), aortic insufficiency, CHF, or pulmonary embolus.

Provide aggressive blood pressure control. Beta-blockers and nitrates are commonly used.[3]

For patients who are hemodynamically unstable, provide the following:

Consultations

Immediately consult with a cardiac surgeon (for ascending aorta or arch) or with a vascular surgeon (for descending aorta) for patients who are hemodynamically unstable or for patients with symptoms of a thoracic aneurysm. Anesthesia and operating room personnel need to be contacted in cases where emergent operative procedures are indicated.

Consult with a vascular surgeon or a cardiac surgeon and a radiologist to determine the optimal studies for assessing the anatomy of the thoracic aneurysm.

Medication Summary

The goal of medical therapy is to reduce the pulse pressure (dP/dt) within the aorta. Reducing the heart rate, the blood pressure (BP), pain, and anxiety are the mainstays of therapy.

Esmolol (Brevibloc)

Clinical Context:  Ultra–short-acting beta1-blocker particularly useful in patients with labile arterial pressure because it can be abruptly discontinued if necessary. Typically used in conjunction with nitroprusside. May be useful as a means to test beta-blocker safety and tolerance in patients with history of obstructive pulmonary disease who are at uncertain risk of bronchospasm from beta blockade. Elimination half-life is 9 min. The objective is a target heart rate of 55-65 bpm.

Labetalol (Normodyne, Trandate)

Clinical Context:  Blocks alpha-, beta1-, and beta2-adrenergic receptor sites, decreasing BP.

Metoprolol (Lopressor)

Clinical Context:  Selective beta1-adrenergic receptor blocker that decreases automaticity of contractions. During IV administration, carefully monitor BP, heart rate, and ECG. When considering conversion from IV to PO dosage forms, use ratio of 2.5 mg PO to 1 mg IV metoprolol.

Propranolol (Inderal, Betachron E-R)

Clinical Context:  Class II antiarrhythmic nonselective beta-adrenergic receptor blocker. Has membrane-stabilizing activity and decreases automaticity of contractions. Not a first-line agent in the treatment of hypertensive emergencies. Do not administer IV in hypertensive emergencies.

Nitroprusside (Nipride, Nitropress)

Clinical Context:  Causes peripheral vasodilation by direct action on venous and arteriolar smooth muscle, thus reducing peripheral resistance. Commonly used IV because of rapid onset and short duration of action. Easily titratable to reach desired effect. Light sensitive; both bottle and tubing should be wrapped in aluminum foil. Prior to initiating, administer beta-blocker to counteract physiologic response of reflex tachycardia that occurs when nitroprusside is used alone. This physiologic response increases shear forces against aortic wall, thus increasing dP/dT.

Class Summary

These agents are used to reduce arterial pressure. Short-acting IV beta blockade and nitrates are very effective in reducing the dP/dt, especially in the ascending aorta. Consider calcium channel blockade in patients with contraindications to beta blockade.

Morphine sulfate (Astramorph, Infumorph)

Clinical Context:  DOC for narcotic analgesia because of reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Like fentanyl, morphine sulfate is easily titrated to desired level of pain control. If administered IV, may be dosed in a number of ways; commonly titrated until desired effect obtained.

Class Summary

Analgesics are used to control pain and to decrease sympathetic tone.

Further Inpatient Care

Unstable patients with thoracic aortic aneurysm (TAA) usually require medical or surgical ICU admission for careful hemodynamic monitoring.

Patients who are symptomatic require admission, as do those in whom a final diagnosis is uncertain.

Some patients with complicating conditions, such as Marfan syndrome or another cardiovascular disease, may require admission for medical stabilization and for more urgent surgical repair, even if they are asymptomatic at presentation.

Indications for surgical repair include the following:[4]

Surgical and other interventional options for TAA repair include the following:[3]

Transfer

Patients with TAA who are symptomatic should only be transferred via advanced life support (ALS) system if the sending facility is unable to provide appropriate operative care.

Complications

Complications of thoracic aortic aneurysm include the following:

Prognosis

In a series of 370 patients with TAA, survival at 1, 5, and 10 years were found to be 88%, 69%, and 56%, respectively.[5]

Patient Education

For patient education resources, see the Heart Health Center and Aortic Aneurysm.

Author

Bret P Nelson, MD, Associate Professor of Emergency Medicine, Director of Emergency Ultrasound, Department of Emergency Medicine, Mount Sinai School of Medicine

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Medical advisory board for EyeLife.<br/>Received consulting fee from Simulab for consulting.

Coauthor(s)

Eric M Isselbacher, MD, MSc, Associate Professor of Medicine, Harvard Medical School; Associate Director, Massachusetts General Hospital Heart Center; Co-Director, Thoracic Aortic Center, Massachusetts General Hospital; Director, MGH Healthcare Transformation Lab

Disclosure: Nothing to disclose.

Theodore I Benzer, MD, PhD, Assistant Professor in Medicine, Harvard Medical School; Director of the ED Observation Unit, Director of Toxicology, Chair of Quality and Safety, Department of Emergency Medicine, Massachusetts General Hospital

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Gary Setnik, MD, Chair, Department of Emergency Medicine, Mount Auburn Hospital; Assistant Professor, Department of Emergency Medicine, Harvard Medical School

Disclosure: Medical Director for: SironaHealth.

Chief Editor

Erik D Schraga, MD, Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Additional Contributors

Edward Bessman, MD, MBA, Chairman and Clinical Director, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University School of Medicine

Disclosure: Nothing to disclose.

References

  1. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation. 2005 Feb 15. 111(6):816-28. [View Abstract]
  2. Clouse WD, Hallett JW Jr, Schaff HV. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA. 1998 Dec 9. 280(22):1926-9. [View Abstract]
  3. Ince H, Nienaber CA. Etiology, pathogenesis and management of thoracic aortic aneurysm. Nat Clin Pract Cardiovasc Med. 2007 Aug. 4(8):418-27. [View Abstract]
  4. Coady MA, Rizzo JA, Elefteriades JA. Developing surgical intervention criteria for thoracic aortic aneurysms. Cardiol Clin. 1999 Nov. 17(4):827-39. [View Abstract]
  5. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin. 1999 Nov. 17(4):615-35; vii. [View Abstract]
  6. Barbant SD, Eisenberg MJ, Schiller NB. The diagnostic value of imaging techniques for aortic dissection. Am Heart J. 1992 Aug. 124(2):541-3. [View Abstract]
  7. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery. 1982 Dec. 92(6):1103-8. [View Abstract]
  8. Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential address. Arch Surg. 1982 Nov. 117(11):1393-400. [View Abstract]
  9. Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 1994 May. 107(5):1323-32; discussion 1332-3. [View Abstract]
  10. Fuster V, Andrews P. Medical treatment of the aorta. I. Cardiol Clin. 1999 Nov. 17(4):697-715, viii. [View Abstract]
  11. Glade GJ, Vahl AC, Wisselink W, et al. Mid-term survival and costs of treatment of patients with descending thoracic aortic aneurysms; endovascular vs. open repair: a case-control study. Eur J Vasc Endovasc Surg. 2005 Jan. 29(1):28-34. [View Abstract]
  12. Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci. 2006 Nov. 1085:339-52. [View Abstract]
  13. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. J Vasc Surg. 2004 Oct. 40(4):670-9; discussion 679-80. [View Abstract]
  14. Pressler V, McNamara JJ. Aneurysm of the thoracic aorta. Review of 260 cases. J Thorac Cardiovasc Surg. 1985 Jan. 89(1):50-4. [View Abstract]
  15. Safi HJ, Miller CC. Thoracic vasculature. Townsend CM, Beauchamp DR, Evers MB, et al, eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 16th ed. Philadelphia, Pa: WB Saunders Co; 2001.
  16. von Allmen RS, Anjum A, Powell JT. Outcomes after endovascular or open repair for degenerative descending thoracic aortic aneurysm using linked hospital data. Br J Surg. 2014 Sep. 101(10):1244-51. [View Abstract]
  17. Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol. 2013 Oct 15. 112(8):1240-5. [View Abstract]
  18. Nation DA, Wang GJ. TEVAR: Endovascular Repair of the Thoracic Aorta. Semin Intervent Radiol. 2015 Sep. 32(3):265-71. [View Abstract]

Descending thoracic aortic aneurysm with mural thrombus at the level of the left atrium.

Descending thoracic aortic aneurysm with mural thrombus at the level of the left atrium.